All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

bunazosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	429	80755-51-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: bunazosin hydrochloride detantol bunazosin bunazosin HCl	Molecular weight: 373.46 Formula: C19H27N5O3 CLOGP: 2.20 LIPINSKI: 0 HAC: 8 HDO: 1 TPSA: 93.81 ALOGS: -2.81 ROTB: 5

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.72 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
BA (Bioavailability)	50 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	1.759		Moderate	0.65
caco2-efflux	Caco-2 efflux ratio (BA/AB)	27.733		Moderate	0.65
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	7.396	10^-6 cm/s	Moderate	0.65
dh-clint	Dog hepatocyte intrinsic clearance	6.295	uL/min/10^6 cells	Moderate	0.65
dppb	Dog plasma protein binding (% unbound)	27.640	%	Moderate	0.65
fcs-ppb	Fetal calf serum protein binding (% unbound)	60.990	%	Moderate	0.65
herg	hERG pIC50	5.420	pIC50	Moderate	0.65
hh-clint	Human hepatocyte intrinsic clearance	3.148	uL/min/10^6 cells	Moderate	0.65
hlm-clint	Human liver microsomal intrinsic clearance	29.785	uL/min/mg protein	Moderate	0.65
hppb	Human plasma protein binding (% unbound)	11.530	%	Moderate	0.65
kinase-safety-class	ACVR2B,EIF2AK3,GRK2,MAPK7,PDK2,PDK4,PIK3CD,PRKDC	8
kinase-selectivity-class	PRKDC,TTK	2
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	13.183		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	15.205		Moderate	0.65
mh-clint	Mouse hepatocyte intrinsic clearance	88.716		Moderate	0.65
mppb	Mouse plasma protein binding (% unbound)	34.420		Moderate	0.65
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	23.442		Moderate	0.65
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	48.450	%	Moderate	0.65
rat-kpuu-brain	Rat brain Kpuu	0.024	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	25.293	uL/min/10^6 cells	Moderate	0.65
rh-fuinc	Rat hepatocyte fraction unbound in incubation	74.300	%	Moderate	0.65
rppb	Rat plasma protein binding (% unbound)	30	%	Moderate	0.65
solubility-dd	Solubility at pH 7.4 in DMSO	860.994	uM	Moderate	0.65

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Essential hypertension	indication	59621000	DOID:10825

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.22	Basic
pKa2	0.87	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST				WOMBAT-PK	KEGG DRUG
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST				WOMBAT-PK	KEGG DRUG
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN					WOMBAT-PK
Ribosyldihydronicotinamide dehydrogenase [quinone]	Enzyme	P16083	NQO2_HUMAN					WOMBAT-PK

External reference:

ID	Source
D01887	KEGG_DRUG
52712-76-2	SECONDARY_CAS_RN
19850	RXNORM
C0054222	UMLSCUI
CHEBI:135576	CHEBI
CHEMBL188185	ChEMBL_ID
DB12230	DRUGBANK_ID
C018176	MESH_SUPPLEMENTAL_RECORD_UI
2472	PUBCHEM_CID
5466	INN_ID
9UUW4V7G2H	UNII
007091	NDDF
007092	NDDF

Pharmaceutical products:

None